Study of Acquired Hemolytic Anemia in Adult Hospitalized Patients

November 26, 2024 updated by: Ahmed Elsayed Mahmoud, Sohag University

Study of the Etiology, Clinical Features and Short Term Outcome of Acquired Hemolytic Anemia in Hospitalized Adult Patients with Non-Neoplastic Disease

the goal of the study is to identify the most common etiological factors and analyze the clinical presentations and laboratory findings in hospitalized patients with acquired hemolytic anemia associated with non-neoplastic diseases.

And to evaluate short-term outcomes, including morbidity and mortality rates, and to determine correlations between specific etiological factors and patient outcomes in these cases.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Mahmoud I Yousef, Lecturer of Internal Medicine
  • Phone Number: 02 0106 596 4083

Study Locations

  • Egypt
      • Sohag, Egypt
        • Faculty of medicine sohag university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients admitted in Internal Medicine department and Intermediate care unit at sohag university hospital

Description

Inclusion Criteria:

  • Adults aged 18 years and older.
  • Patients diagnosed with acquired hemolytic anemia.
  • Patients must be hospitalized in the Internal Medicine department at the time of diagnosis of acquired hemolytic anemia during the study period
  • Patients (or their legal representatives) must provide informed

Exclusion Criteria:

  • Patients with underlying neoplastic diseases.
  • Patients with hereditary hemolytic anemia.
  • Patients or their representatives who do not consent to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intensive care unit admission of the patients due to progression of the disease complications.
Time Frame: through study completion, an average of 6 months
Primary outcome will be ICU admission due to progression of the disease complications.
through study completion, an average of 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality within duration of hospital admission
Time Frame: through study completion, an average of 6 months
Secondary outcome will be mortality within duration of hospital admission
through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2024

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

November 22, 2024

First Submitted That Met QC Criteria

November 26, 2024

First Posted (Estimated)

November 27, 2024

Study Record Updates

Last Update Posted (Estimated)

November 27, 2024

Last Update Submitted That Met QC Criteria

November 26, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AEMahmoud

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemolytic Anemia

Clinical Trials on blood samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe